Hanwha Life Secures Six-Month Exclusive Use Right for Diabetes Management Rider

Hanwha Life announced on December 10 that it has obtained a six-month exclusive use right from the Korea Life Insurance Association for a new rider that supports blood glucose management for diabetes patients.

The rider granted exclusive use rights is the "Diabetes Continuous Glucose Monitoring Device Cost Support" rider. This rider has been included in the Hanwha Life H Diabetes Insurance product, which was launched last month.

With this rider, customers diagnosed with diabetes who use a continuous glucose monitoring (CGM) device based on a doctor's prescription are eligible to receive the device cost as an insurance benefit once per year.

Hanwha Life 63 Building. Hanwha Life

A continuous glucose monitoring device is a personal medical device that records blood glucose changes for 24 hours through a sensor attached to the skin. As it allows users to monitor blood glucose fluctuations without repeated blood sampling, its use has been increasing recently. It also enables users to check their body's response to meals, exercise, and medications, providing practical support for daily management.

Hanwha Life's analysis of 360,000 diabetes-related insurance claims over the past five years (2021-2025) also highlights the need for management. Among customers who made their first insurance claim for diabetes, the proportion of those in their 30s and 40s increased from 27.3% to 35.4%. The average medical expense within the first two years after diagnosis was about 3.33 million won, approximately 1.4 times higher than that of hypertension patients (about 2.42 million won).

Reflecting these changes, Hanwha Life introduced the industry's first prevention-focused diabetes management model that links CGM prescriptions to insurance coverage. This is regarded as a practical benefit that can help reduce management gaps for diabetes patients with significant blood glucose variability.

Including this rider, Hanwha Life has secured 7 out of the 12 exclusive use rights registered with the Korea Life Insurance Association this year, achieving outstanding results in the competition for product originality.

Lee Sanghee, Head of Product Development at Hanwha Life, said, "Recently, blood glucose management in daily life has become a new health trend, and the use of smart management technologies such as continuous glucose monitoring devices is rapidly increasing. This rider proactively reflects these changes by providing coverage for medical devices that customers actually use, and we will continue to develop benefits that customers can truly experience."

This content was produced with the assistance of AI translation services.